Deadline Approaches for Soleno Therapeutics Investors: Class Action Reminder
Faruqi & Faruqi, LLP, a prominent national securities law firm, is urging investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who acquired securities between March 26, 2025 and November 4, 2025, to take note of an upcoming deadline for a federal securities class action lawsuit. The firm emphasizes that the deadline for seeking lead plaintiff status is May 5, 2026.
Under the alleged complaint, Soleno and its executives are accused of breaching federal securities laws by making misleading statements and not disclosing crucial safety concerns linked to their drug candidate DCCR. These concerns surfaced during Phase 3 clinical trials, suggesting that the drug posed significant risks that were not properly communicated to investors or regulatory bodies.
The issue gained traction when a report by Scorpion Capital LLC highlighted potential dangers associated with DCCR, leading to a sharp decline in stock prices from over $77 to around $68 in August 2025. Further complicating matters, Soleno disclosed a patient’s death after DCCR administration on September 10, 2025, resulting in another significant drop in stock value, this time falling to approximately $57 per share by September 11, 2025.
By November 2025, following a shareholder meeting that revealed financial setbacks and increasing concerns within the Prader-Willi syndrome community, Soleno's share price experienced yet another significant drop. The closing price plummeted to about $47 per share from $64 in a single day.
As investors and potential class members consider their legal options, it’s important to note that a lead plaintiff is the investor with the highest financial interest in the case, who can adequately represent the class. Those interested in taking action have the option to do so through legal counsel or to remain passive class members. The pivotal role of the lead plaintiff will shape how the class action case progresses in court.
For any members of the class or individuals with insight into Soleno's recent conduct, Faruqi & Faruqi encourages you to reach out. This includes whistleblowers, prior employees, or anyone else with pertinent information.
For more information regarding the ongoing developments of the Soleno Therapeutics class action, interested parties can visit Faruqi & Faruqi’s website or directly contact Josh Wilson, a senior partner at the firm, for legal guidance. As the situation unfolds, investors and concerned stakeholders are urged to keep an eye on the deadlines and developments in the case, ensuring they can make informed decisions moving forward.
Faruqi & Faruqi has garnered a reputation for its diligent representation of investors, successfully recovering hundreds of millions since its establishment in 1995. As such, the firm stands ready to assist those affected by the current situation with Soleno Therapeutics. Updates regarding the case will also be available on their various social media platforms, providing continual progress reports to investors following the situation closely.
Under the alleged complaint, Soleno and its executives are accused of breaching federal securities laws by making misleading statements and not disclosing crucial safety concerns linked to their drug candidate DCCR. These concerns surfaced during Phase 3 clinical trials, suggesting that the drug posed significant risks that were not properly communicated to investors or regulatory bodies.
The issue gained traction when a report by Scorpion Capital LLC highlighted potential dangers associated with DCCR, leading to a sharp decline in stock prices from over $77 to around $68 in August 2025. Further complicating matters, Soleno disclosed a patient’s death after DCCR administration on September 10, 2025, resulting in another significant drop in stock value, this time falling to approximately $57 per share by September 11, 2025.
By November 2025, following a shareholder meeting that revealed financial setbacks and increasing concerns within the Prader-Willi syndrome community, Soleno's share price experienced yet another significant drop. The closing price plummeted to about $47 per share from $64 in a single day.
As investors and potential class members consider their legal options, it’s important to note that a lead plaintiff is the investor with the highest financial interest in the case, who can adequately represent the class. Those interested in taking action have the option to do so through legal counsel or to remain passive class members. The pivotal role of the lead plaintiff will shape how the class action case progresses in court.
For any members of the class or individuals with insight into Soleno's recent conduct, Faruqi & Faruqi encourages you to reach out. This includes whistleblowers, prior employees, or anyone else with pertinent information.
For more information regarding the ongoing developments of the Soleno Therapeutics class action, interested parties can visit Faruqi & Faruqi’s website or directly contact Josh Wilson, a senior partner at the firm, for legal guidance. As the situation unfolds, investors and concerned stakeholders are urged to keep an eye on the deadlines and developments in the case, ensuring they can make informed decisions moving forward.
Faruqi & Faruqi has garnered a reputation for its diligent representation of investors, successfully recovering hundreds of millions since its establishment in 1995. As such, the firm stands ready to assist those affected by the current situation with Soleno Therapeutics. Updates regarding the case will also be available on their various social media platforms, providing continual progress reports to investors following the situation closely.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.